A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors

被引：0
|
作者：
Wentzel, K. [1 ]
Peguero, J. [2 ]
Kummar, S. [3 ]
Lorusso, P. [4 ]
Mehnert, J. M. [5 ]
Spira, A. I. [6 ]
Naing, A.
Hamid, O. [7 ,8 ]
Mehmi, I. [9 ]
Benhadji, K. [10 ]
Alland, L. [11 ]
Hu, X. [12 ]
Xiao, H. [13 ]
Bao, X. [14 ]
Chen, J. [15 ]
Gong, Y. [16 ]
Liu, X. S. [17 ]
机构：
[1] Angeles Clin & Res Inst, Dept Oncol, Los Angeles, CA USA
[2] Oncol Consultants, Dept Oncol, Houston, TX USA
[3] OHSU Knight Canc Inst, Ctr Hlth & Healing South Waterfront, Div Hematol & Med Oncol, Portland, OR USA
[4] Yale Sch Med, Radiol & Biomed Imaging, Med Oncol Dept, New Haven, CT USA
[5] Laura & Isaac Perlmutter Canc Ctr, Hematol & Med Oncol, New York, NY USA
[6] Virginia Canc Specialists, Res Dept, Fairfax, VA USA
[7] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX USA
[8] Angeles Clin & Res Inst, Los Angeles, CA USA
[9] Angeles Clin & Res Inst, Med Oncol, Los Angeles, CA USA
[10] GV20 Therapeut, Clin Dept, Cambridge, MA USA
[11] GV20 Therapeut, Med Oncol, Cambridge, MA USA
[12] GV20 Therapeut, Biostat, Cambridge, MA USA
[13] GV20 Therapeut, Clin Operat, Cambridge, MA USA
[14] GV20 Therapeut, Biol, Cambridge, MA USA
[15] GV20 Therapeut, CMC & Qual, Cambridge, MA USA
[16] GV20 Therapeut, Business, Cambridge, MA USA
[17] GV20 Therapeut, G&A, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1000MO
引用
收藏
页码：S680 / S681
页数：2
相关论文
共 50 条
  • [1] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [2] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
    Song, Zhengbo
    Hui, Ai-min
    Wu, Zhuli
    Liu, Huilong
    Cheng, Xiangdong
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
    Balmana, Judith
    Tung, Nadine M.
    Isakoff, Steven J.
    Grana, Begona
    Ryan, Paula D.
    Rafi, Rezvan
    Tracy, Michael
    Winer, Eric
    Baselga, Jose
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [5] BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
    Cousin, Sophie
    Blay, Jean-Yves
    Garcia, Irene Brana
    De Bono, Johann S.
    Le Tourneau, Christophe
    Moreno, Victor
    Trigo, Jose Manuel
    Hann, Christine L.
    Azad, Arun
    Im, Seock-Ah
    Ferron-Brady, Geraldine
    Datta, Antara
    Wu, Yuehui
    Horner, Thierry
    Kremer, Brandon Edward
    Dhar, Arindam
    O'Dwyer, Peter J.
    Shapiro, Geoffrey
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
  • [7] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors
    Vaena, Dan
    Patnaik, Amita
    Hamilton, Erika
    Olweny, Judy
    Hunter, John
    Adewoye, Adeboye Henry
    ElNaggar, Adam
    Rasco, Drew
    CANCER RESEARCH, 2019, 79 (13)
  • [9] An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
    Hofheinz, Ralf-Dieter
    Al-Batran, Salah-Eddin
    Hochhaus, Andreas
    Jaeger, Elke
    Reichardt, Volker L.
    Fritsch, Holger
    Trommeshauser, Dirk
    Munzert, Gerd
    CLINICAL CANCER RESEARCH, 2010, 16 (18) : 4666 - 4674
  • [10] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
12345